The World Health Organisation (WHO) has raised serious concerns that HIV medication shortages sparked by cuts to USAID will ...

United Nations Permanent Forum on indigenous issues, Agenda item 4: Discussion on the six mandated areas of the Permanent Forum (economic and social development, culture, environment, education, ...

Anti-retroviral drugs (ARVs) meant to save lives and designed to fight HIV are being used by addicts to produce a highly potent and dangerous new drug -- nyaope, an investigation by Check Point can ...

Ten thousand children were infected with HIV in Asia and the Pacific in 2023, roughly 30 each day. Although PMTCT services ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Kintampo, (Bono East), April 25, GNA – The Management of the Kintampo Waterfalls in the Bono East Region in collaboration ...

No matter where you find him, Dr. Ho is taking a leadership role and working to make spaces in Pittsburgh safer and more ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

Real-world data indicated ART with DTG+3TC was effective and well tolerated among patients with HIV infection regardless of prior ART exposure.

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

The National Institutes of Health’s sweeping cuts of grants that fund scientific research are inflicting pain almost ...